Ionis Pharmaceuticals Inc. Sets Itself Up for Growth
Ionis Pharmaceuticals' (NASDAQ: IONS) third-quarter earnings were a bit humdrum considering partner Biogen (NASDAQ: BIIB) spilled the beans on sales of Spinraza a few weeks ago when it reported its earnings. Nevertheless, the biotech is setting itself up for solid growth with two additional drugs under review by regulators.
Metric
Q3 2017
Source: Fool.com
Ionis Pharmaceuticals Inc. Stock
€47.38
-1.250%
Currently there is a rather positive sentiment for Ionis Pharmaceuticals Inc. with 26 Buy predictions and 5 Sell predictions.
As a result the target price of 56 € shows a slightly positive potential of 18.19% compared to the current price of 47.38 € for Ionis Pharmaceuticals Inc..
